Clinical Trial Update: Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of ibrutinib with bortezomib and dexamethasone in relapsed/refractory multiple myeloma has completed with posted result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Ibrutinib (ibrutinib)

Snippet

Sponsor: Pharmacyclics Switzerland GmbH | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2020-01-02